



Module 6

How is Duchenne muscular dystrophy (DMD) managed?



Module summary




Individuals with DMD are cared for by a multidisciplinary team^{1,2}

Care is individualized across the lifespan based on stage of disease, therapeutic response, and tolerance^{1,2}




Treatment goals in DMD are to preserve function and quality of life^{1,2}

The focus is on maintaining ambulation, maintaining cardiac and respiratory function, managing complications, and preserving quality of life^{1,2}



Treatment of DMD requires a multifaceted approach using both disease-modifying and symptom-based approaches³


Currently, corticosteroids are the mainstay of care in DMD, however, guidelines are evolving as new therapeutics become approved^{1,4}



Some approved and investigational therapies aim to restore dystrophin production³

Even low dystrophin expression has been associated with delayed clinical milestones, compared to no dystrophin expression⁵

Who makes up the multidisciplinary team caring for individuals with DMD?



Management of individuals with DMD requires a multidisciplinary team approach to individualize care based on the individual's needs, stage of disease, therapeutic response, and tolerance across their lifespan^{1,2}

What are the main goals of treatment for DMD?

Maintain ambulation



- Prevent muscle atrophy^{1,2}
- Delay loss of ambulation^{1,3-5}
- Improve muscle function⁴⁻⁶
- Preserve upper limb function^{3,4}

Maintain cardiac and respiratory function



- Delay respiratory decline^{4,5,7,8}
- Delay the onset of cardiomyopathy¹
- Prevent heart failure⁹

Manage disease complications



- Inflammatory damage to muscle²
- Cardiomyopathy^{9,10}
- Skeletal deformities^{3,11}
- Respiratory failure^{7,12}
- Managed by pharmacologic and non-pharmacologic interventions³
- Improve psychosocial management and QoL, growing priorities as life expectancy increases³

Preserve QoL



- Prolong survival^{3,9}
- Prolong independent ambulation^{3,6,9}

Treatment of DMD requires a multifaceted approach using both disease-modifying and symptom-based approaches¹

DMD, Duchenne muscular dystrophy; QoL, quality of life.

1. Yao S, et al. *Front Cell Dev Biol.* 2021;9:689533; 2. Arpan I, et al. *Neurology.* 2014;83:974–980; 3. Birnkrant DJ, et al. *Lancet Neurol.* 2018;17:251–267; 4. McDonald CM, et al. *Lancet.* 2018;391(10119):451–461; 5. Mitelman O, et al. *J Neuromuscul Dis.* 2022;9:39–52; 6. Henricson EK, et al. *Muscle Nerve.* 2013;48:55–67; 7. Finder JD, et al. *Am J Resp Crit Care Med.* 2004;170:456–465; 8. Khan N, et al. *J Neuromuscul Dis.* 2019;6:213–225; 9. Birnkrant DJ, et al. *Lancet Neurol.* 2018;17:347–361; 10. Allen HD, et al. *PLoS Curr.* 2013;5.ecurrents.md.2cc69a1dae4be7dfe2bcb420024ea865; 11. Cervellati S, et al. *Eur Spine J.* 2004;13:441–448; 12. Ishikawa W, et al. *Neuromuscul Disord.* 2011;21:47–51.

In the era of new therapeutics, are DMD care guidelines evolving?



Management of DMD requires a multidisciplinary approach^{1–4}



Current DMD care guidelines focus on steroids as the mainstay of DMD treatment^{1–3}



Recent consensus guidelines provide initial recommendations for integrating approved gene therapy into DMD care^{1,2,4,5}



Consensus expert opinion available on the use of eteplirsen but not other PMOs⁴


With the approval of new therapeutics, regular updates to DMD care guidelines are essential^{4,5}

DMD, Duchenne muscular dystrophy; PMO, phosphorodiamidate morpholino oligomer.

1. Birnkrant DJ, et al. *Lancet Neurol*. 2018;17:251–267; 2. Birnkrant DJ, et al. *Lancet Neurol*. 2018;17:347–361; 3. Birnkrant DJ, et al. *Lancet Neurol*. 2018;17:445–455; 4. Rivera SR, et al. *PLoS One*. 2020;15:e0240687;

5. Wolff JM, et al. *Neuromuscul Disord*. 2025;35:106208.

What therapeutic strategies are used in DMD (approved and investigational)?^{1,2}




ASO, antisense oligonucleotide; cAMP, cyclic adenosine monophosphate; cGMP, cyclic guanosine monophosphate; DMD, Duchenne muscular dystrophy; nNOS, neuronal nitric oxide synthase; PDE5, phosphodiesterase type 5; snRNA, small nuclear RNA.

Image adapted from Yao S, et al. *Front Cell Dev Biol.* 2021;9:689533, licensed under a CC-BY 4.0 Creative Commons license; doi: 10.3389/fcell.2021.689533.

1. Yao S, et al. *Front Cell Dev Biol.* 2021;9:689533; 2. Mbakam CH, et al. *Front Med (Lausanne).* 2022;9:859930.

Do low levels of dystrophin expression impact DMD disease progression?

Spontaneous, endogenous exon skipping associated with certain deletion mutations in *DMD* can lead to dystrophin expression, resulting in significant variation in disease trajectories.



Compared to no dystrophin, levels <5% (and as low as <0.5%) were associated with a milder DMD clinical phenotype, including delays in LoA and decline in cardiorespiratory function (measured by VC <50% and LVEF <55%)* and increased survival.

Restoration of even very low dystrophin expression has been associated with delayed clinical milestones in individuals with DMD, suggesting that any amount of dystrophin expression may have therapeutic benefit

*Data not shown.

DMD, Duchenne muscular dystrophy; LoA, loss of ambulation; LVEF, left ventricular ejection fraction; NS, not significant; VC, vital capacity.

Images used with permission of The Authors, from de Feraudy Y, et al. *Ann Neurol.* 2021;89:280–292; permission conveyed through Copyright Clearance Center, Inc.

de Feraudy Y, et al. *Ann Neurol.* 2021;89:280–292.